1. Emerging drugs for dementia with Lewy Bodies: a review of Phase II & III trials
    Magdalena I. Tolea et al, 2023, Expert Opinion on Emerging Drugs CrossRef
  2. Long‐term effects of cholinesterase inhibitors and memantine on cognitive decline, cardiovascular events, and mortality in dementia with Lewy bodies: An up to 10‐year follow‐up study
    Hong Xu et al, 2024, Alzheimer's & Dementia CrossRef
  3. The use of Akatinol Memantine in the treatment of gait disturbances in Parkinson’s disease
    I.V. Miliukhina et al, 2020, Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova CrossRef
  4. Vertigoheel promotes rodent cognitive performance in multiple memory tests
    Kerstin Ott et al, 2023, Frontiers in Neuroscience CrossRef
  5. Caregiver Experiences and Burden in Moderate-Advanced Dementia With Lewy Bodies
    Melissa J. Armstrong et al, 2024, Neurology Clinical Practice CrossRef
  6. Speech disorders in neurodegenerative diseases as dysphasia manifestation
    E.E. Vasenina et al, 2020, Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova CrossRef
  7. The use of donepezil in gait disorders in eldery patients with dementia
    A. D. Chebotareva et al, 2019, Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova CrossRef
  8. Molecular Factors Mediating Neural Cell Plasticity Changes in Dementia Brain Diseases
    Wojciech Kozubski et al, 2021, Neural Plasticity CrossRef
  9. Medikamentöse Therapie der Demenz
    Mareike Kirsch et al, 2022, DMW - Deutsche Medizinische Wochenschrift CrossRef
  10. Pathological correlates of cognitive decline in Parkinson’s disease: from molecules to neural networks
    N. I Novikov et al, 2023, Биохимия CrossRef

  11. Cognitive Impairment in Parkinson’s Disease: What We Know so Far


    Celia Painous et al, 2020, Research and Reviews in Parkinsonism CrossRef
  12. Practical aspects of using donepezil in the treatment of dementia
    A.D. Chebotareva et al, 2020, Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova CrossRef
  13. Use of Cholinesterase Inhibitors in Non-Alzheimer’s Dementias
    Paul Noufi et al, 2019, Drugs & Aging CrossRef
  14. Effects of Akatinol Memantine on Gait Disturbances at the Developed Stages of Parkinson’s Disease
    I. V. Miliukhina et al, 2021, Neuroscience and Behavioral Physiology CrossRef
  15. Parkinson’s Disease–Mild Cognitive Impairment (PD-MCI): A Useful Summary of Update Knowledge
    Davide Maria Cammisuli et al, 2019, Frontiers in Aging Neuroscience CrossRef
  16. Emulated Clinical Trials from Longitudinal Real-World Data Efficiently Identify Candidates for Neurological Disease Modification: Examples from Parkinson’s Disease
    Daphna Laifenfeld et al, 2021, Frontiers in Pharmacology CrossRef
  17. Clinical Guidelines for Cognitive Disorders in Elderly and Older Patients
    A.N. Bogolepova et al, 2021, Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova CrossRef
  18. Patterns of dementia treatment in older adults with Parkinson’s disease using nationwide medical claims data
    Bora Yoon et al, 2022, BMC Geriatrics CrossRef
  19. Mild cognitive impairment in patients with Parkinson’s disease: An updated mini-review and future outlook
    Rwei-Ling Yu et al, 2022, Frontiers in Aging Neuroscience CrossRef